Skip to main content

Lupus

      Lupus Panel
      RT @Yuz6Yusof: #ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE &
      #ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE & Cardiovascular (both 23%), then cancer & infection.SLE deaths common in younger. African-American died younger vs White. Need to improve with therapies we now have @RheumNow https://t.co/4tDhr1Eodm
      RT @Yuz6Yusof: #ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study
      #ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study which 16% developed advanced CKD, risk was reduced if remission achieved by 12 mths of diagnosis. =>1 flare & shorter time-on-therapy increased risk @RheumNow #ACRBest https://t.co/swYn2g4hqe
      RT @bella_mehta: #SLE mortality in South Carolina Lupus Cohort
      Standardized mortality ratio (SMR) is higher in blacks
      Hi
      2 years ago
      #SLE mortality in South Carolina Lupus Cohort Standardized mortality ratio (SMR) is higher in blacks Higher SLICC scores in blacks abst#2106 #ACR22 @rheumnow https://t.co/NAdNhUHsbc
      RT @Janetbirdope: New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 m
      2 years ago
      New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 mg bid and 12 mg OD. Skin via CLASI-50 & other endpoints also positive. Awaiting phase III. Abst1117 #ACR22 @RheumNow https://t.co/fZI3AV5pML
      RT @RichardPAConway: Hidekawa et al. HCQ use assoc reduced severe infection in LUNA SLE registry, HR 0.26. ?due to bette
      Hidekawa et al. HCQ use assoc reduced severe infection in LUNA SLE registry, HR 0.26. ?due to better disease control rather than anti-infectious role, but HR 0.32 in multivariable model including SLEDAI. @RheumNow #ACR22 Abstr#2059 https://t.co/EgTJOAymoF https://t.co/gmchk9ZS5L
      RT @RichardPAConway: Figueroa Parra @AliDuarteMD et al. Multimorbidity in SLE. Higher at classification - due to non-SLE
      Figueroa Parra @AliDuarteMD et al. Multimorbidity in SLE. Higher at classification - due to non-SLE assoc. SLE-assoc drive increased accumulation over time but non-SLE assoc also increased @RheumNow #ACR22 Abstr#2091 https://t.co/6IyhovSNYA https://t.co/qmYfoqCTtz
      RT @Yuz6Yusof: #ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT
      #ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT showed discordance (12-30%).When discordant, SRI-4 classified more pts as responders vs BICLA. Concordance higher at 52 vs 24 wks. Vital to interpret both outcomes @RheumNow https://t.co/prSfTrv0E8
      RT @Yuz6Yusof: #ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidem
      #ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidemiology? A study identified urbanicity and area deprivation index were associated with SLE diagnosis. Could those living in the city = better access and diagnosis? @RheumNow https://t.co/PsNt8vQufs
      Urine Proteomics in SLE with Dr. Michelle Petri

      Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarke
      2 years ago
      Urine Proteomics in SLE with Dr. Michelle Petri Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22. https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB